Saleh Mansoor, Chandrashekar Darshan Shimoga, Shahin Sayed, Agarwal Sumit, Kim Hyung-Gyoon, Behring Michael, Shaikh Asim Jamal, Moloo Zahir, Eltoum Isam-Eldin A, Yates Clayton, Varambally Sooryanarayana, Manne Upender
Department of Medicine, University of Alabama at Birmingham, Birmingham 35233, AL, United States; Department of Hematology-Oncology, the Aga Khan University, Nairobi, Kenya; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham 35233, AL, United States.
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.
Transl Oncol. 2021 Jul;14(7):101086. doi: 10.1016/j.tranon.2021.101086. Epub 2021 Apr 8.
Triple-negative breast cancer (TNBC) patients of various ethnic groups often have discrete clinical presentations and outcomes. Women of African descent have a disproportionately higher chance of developing TNBCs. The aim of the current study was to establish the transcriptome of TNBCs from Kenyan (KE) women of Bantu origin and compare it to those TNBCs of African-Americans (AA) and Caucasians (CA) for identifying KE TNBC-specific molecular determinants of cancer progression and potential biomarkers of clinical outcomes.
Pathology-confirmed TNBC tissues from Kenyan women of Bantu origin (n = 15) and age and stage range matched AA (n = 19) and CA (n = 23) TNBCs of patients from Alabama were included in this study. RNA was isolated from paraffin-embedded tissues, and expression was analyzed by RNA sequencing.
At clinical presentation, young KE TNBC patients have tumors of higher stages. Differential expression analysis identified 160 up-regulated and 178 down-regulated genes in KE TNBCs compared to AA and CA TNBCs. Validation analyses of the TCGA breast cancer data identified 45 KE TNBC-specific genes that are involved in the apoptosis (ACTC1, ERCC6 and CD14), cell proliferation (UHRF2, KDM4C, UHMK1, KCNH5, KRT18, CSF1R and S100A13), and Wnt signaling (BCL9L) pathways.
In this study, we identified biomarkers that are specific for KE TNBC patients of Bantu origin. Further study with a larger sample size of matched tumors could confirm our findings. If biologically confirmed, these molecular determinants could have clinical and biological implications and serve as targets for development of personalized therapeutics for KE TNBC patients.
不同种族的三阴性乳腺癌(TNBC)患者通常有不同的临床表现和预后。非洲裔女性患TNBC的几率相对更高。本研究的目的是建立来自肯尼亚(KE)班图族女性的TNBC转录组,并将其与非裔美国人(AA)和高加索人(CA)的TNBC转录组进行比较,以确定KE TNBC中癌症进展的特异性分子决定因素以及临床预后的潜在生物标志物。
本研究纳入了来自肯尼亚班图族女性的经病理确诊的TNBC组织(n = 15),以及年龄和分期范围相匹配的来自阿拉巴马州的AA(n = 19)和CA(n = 23)TNBC患者。从石蜡包埋组织中分离RNA,并通过RNA测序分析其表达。
在临床表现方面,年轻的KE TNBC患者肿瘤分期更高。差异表达分析确定,与AA和CA TNBC相比,KE TNBC中有160个基因上调,178个基因下调。对TCGA乳腺癌数据的验证分析确定了45个KE TNBC特异性基因,这些基因参与凋亡(ACTC1、ERCC6和CD14)、细胞增殖(UHRF2、KDM4C、UHMK1、KCNH5、KRT18、CSF1R和S100A13)以及Wnt信号通路(BCL9L)。
在本研究中,我们确定了班图族KE TNBC患者特有的生物标志物。对更大样本量的匹配肿瘤进行进一步研究可能会证实我们的发现。如果得到生物学证实,这些分子决定因素可能具有临床和生物学意义,并可作为开发KE TNBC患者个性化治疗方法的靶点。